In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No

Polman CH O’Connor P Havrdova E . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Kappos L Radue EW O’Connor P .; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Gold R Kappos L Arnold DL .; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.

Jacobs LD Cookfair DL Rudick RA .; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–294.

PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.

Miller DH Soon D Fernando KT .; AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68: 1390–1401.

Li DK Paty DW Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999; 46: 197–206.

Comi G Martinelli V Rodegher M .; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503–1511.

Cohen JA Barkhof F Comi GC . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Fox R Miller DH Phillips JT . Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

Shirani A Zhao Y Karim ME . Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308: 247–256.

Trojano M Pellegrini F Fuiani A . New natural history of interferon-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300–306.

Tedeholm H Lycke J Skoog B . Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler J 2012; Nov 1 (epub ahead of print).

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 14–19.

Havrdova E Galetta S Stefoski D . Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(Suppl 3): S3–S7.